MedPath

Ifosfamide

Generic Name
Ifosfamide
Brand Names
Ifex
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
3778-73-2
Unique Ingredient Identifier
UM20QQM95Y

Overview

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Background

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication

Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.

Associated Conditions

  • Bladder Cancer
  • Cervical Cancer
  • Ewing's Sarcoma
  • Head And Neck Cancer
  • Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma (NHL)
  • Osteosarcoma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Small Cell Lung Cancer (SCLC)
  • Soft Tissue Sarcoma
  • Testicular Germ Cell Cancer
  • Thymoma

FDA Approved Products

IFOSFAMIDE
Manufacturer:Baxter Healthcare Corporation
Route:INTRAVENOUS
Strength:1 g in 20 mL
Approved: 2019/10/30
NDC:10019-927
IFOSFAMIDE
Manufacturer:Baxter Healthcare Corporation
Route:INTRAVENOUS
Strength:1 g in 20 mL
Approved: 2014/08/28
NDC:10019-925
IFOSFAMIDE
Manufacturer:Baxter Healthcare Corporation
Route:INTRAVENOUS
Strength:3 g in 60 mL
Approved: 2019/10/30
NDC:10019-929
Ifosfamide
Manufacturer:Hikma Pharmaceuticals USA Inc.
Route:INTRAVENOUS
Strength:50 mg in 1 mL
Approved: 2023/04/19
NDC:0143-9530
Ifosfamide
Manufacturer:Hikma Pharmaceuticals USA Inc.
Route:INTRAVENOUS
Strength:50 mg in 1 mL
Approved: 2023/04/19
NDC:0143-9531

Singapore Approved Products

HOLOXAN FOR INJECTION 1 g/25 ml
Manufacturer:BAXTER ONCOLOGY GMBH
Form:INJECTION, POWDER, FOR SOLUTION
Strength:1 g/25 ml
Online:Yes
Approved: 1988/06/08
Approval:SIN01699P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath